By Kristin Brooks, Managing Editor, Contract Pharma03.03.21
As drug development trends change, so too must manufacturing processes and equipment. Contract Pharma looks into how the pandemic has impacted equipment needs, the latest technologies being leveraged in manufacturing, as well as continued challenges and where advances have been made across digital technologies, cell and gene manufacture, single use technologies, and continuous manufacturing.
Pharma & Biopharma Trends
Personalized medicines topped one-third of all new drug approvals in 2020 for the third time in the last four years, according to a recent report from The Personalized Medicine Coalition. The U.S. FDA approved 19 personalized therapies, one cell-based immunotherapy, and eight new diagnostic indications, accounting for 39% of the new drugs FDA approved last year.1
Key among the trends driving equipment needs is the growing number of complex and specialized therapies produced in small quantities, as well as drug delivery of therapies administered at home. In addition to flexibility for customization, is greater automation and modularity to address changing needs.
<
Pharma & Biopharma Trends
Personalized medicines topped one-third of all new drug approvals in 2020 for the third time in the last four years, according to a recent report from The Personalized Medicine Coalition. The U.S. FDA approved 19 personalized therapies, one cell-based immunotherapy, and eight new diagnostic indications, accounting for 39% of the new drugs FDA approved last year.1
Key among the trends driving equipment needs is the growing number of complex and specialized therapies produced in small quantities, as well as drug delivery of therapies administered at home. In addition to flexibility for customization, is greater automation and modularity to address changing needs.
<
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
